Search Results - Juliane Manitz

  • Showing 1 - 4 results of 4
Refine Results
  1. 1
    Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival

    Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival by Juliane Manitz, Sandra P. D’Angelo, Andrea B. Apolo, S. Peter Eggleton, Marcis Bajars, Oliver Bohnsack, James L. Gulley

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the JAVELIN Bladder 100 Trial

    Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Analyses of Patient-reported Outcomes and Quality-adjusted Time Without Symptoms or Toxicity from the J... by Petros Grivas, Jeanny B. Aragon‐Ching, Joaquim Bellmunt, Yohann Loriot, Miguel Á. Climent Durán, Srikala S. Sridhar, Po‐Jung Su, Se Hoon Park, Evgeny Kopyltsov, Yoshiaki Yamamoto, Natalia Jacob, Jason Hoffman, Karin Tyroller, Juliane Manitz, Mairead Kearney, Michael Schlichting, Thomas Powles

    Published 2025
    Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis

    Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis by Andrea B. Apolo, John Ellerton, Jeffrey R. Infante, Manish Agrawal, Michael S. Gordon, Raid Aljumaily, Theodore Stewart Gourdin, Luc Dirix, Keunwook Lee, Matthew H. Taylor, Patrick Schöffski, Ding Wang, Alain Ravaud, Juliane Manitz, Gregory K. Pennock, Mary Ruisi, James L. Gulley, Manish R. Patel

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors

    Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors by Guru Sonpavde, Juliane Manitz, Chen Gao, Darren Tayama, Constanze Kaiser, Daniel Hennessy, Doris Makari, Ashok Gupta, Shaad E. Abdullah, Günter Niegisch, Jacob Rosenberg, Dean F. Bajorin, Petros Grivas, Andrea B. Apolo, Robert Dreicer, Noah M. Hahn, Matthew D. Galsky, Andrea Necchi, Sandy Srinivas, Thomas Powles, Toni K. Choueiri, Gregory R. Pond

    Published 2020
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: